May 7th 2024
Investigators aimed to assess effectiveness of early and continuous enrichment intervention on motor, cognitive, and functional skills in infants with CP.
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Adolescents with ADHD Need Special Attention
October 29th 2007Adolescents with ADHD are different from other patients. Impulsiveness and inattention pose bigger problems than hyperactivity, which can translate into lower medication adherence and growing behavioral problems. And adolescent girls tend to exhibit more problems than boys in the same age range.
ADHD pharmacotherapy: Prescribe with safety in mind and monitor results with vigilance
June 14th 2007The keys to optimal use of psychostimulant and nonstimulant medications for attention deficit hyperactivity disorder are careful screening of patients, appropriate dosage regulation, and?most of all?close monitoring of both positive and adverse outcomes.
Brain's fear center smaller in most severely socially-impaired males with autism spectrum disorders
January 12th 2007Researchers funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) and National Institute on Child Health and Human Development (NICHD) have discovered that the brain's fear hub likely becomes abnormally small in the most severely socially-impaired males with autism spectrum disorder. New findings suggest that social fear in autism may initially trigger a hyperactive, abnormally enlarged amygdala, which eventually gives way to a toxic adaptation that kills amygdala cells and shrinks the structure, said Richard Davidson, Ph.D., and colleagues at the University of Wisconsin.
ADHD pharmacotherapy: Prescribe with safety in mind and monitor results with vigilance
December 1st 2006The keys to optimal use of psychostimulant and nonstimulant medications for attention deficit hyperactivity disorder are careful screening of patients, appropriate dosage regulation, and-most of all-close monitoring of both positive and adverse outcomes.
Transdermal delivery of methylphenidate passes a test of efficacy in ADHD
June 8th 2006New research reported at the annual meeting of the American Psychiatric Association in Toronto in May shows that Shire Pharmaceutical Group's methylphenidate transdermal system (Daytrana) appears a safe and well-tolerated alternative to OROS methylphenidate, and is equally efficacious.
ADHD study supports lower lead exposure limits
May 1st 2006A new study on potential interactions between genetic and environmental factors in ADHD suggests that current limits on lead exposure are too high. Lead exposure below the current limits allowed by Environmental Protection Agency regulations produced measurable impairment of executive functions, especially in boys, who have a specific variation in the DRD4 dopamine receptor gene.
Study: Ritalin effective in preschoolers with ADHD
October 10th 2005The longest and most complex study of methylphenidate (Ritalin) in preschool children shows that it can be safe and effective for some children in that age group who have attention deficit hyperactive disorder (ADHD), according to the study's lead author.
The question of the day: Is there an autism epidemic?
October 8th 2005The answer? We don't really know, according to Craig Newschaffer, PhD, associate professor at the Johns Hopkins School of Public Health. But fears of an autism epidemic have been overblown by the press and advocacy groups, said Dr. Newschaffer, speaking at the American Academy of Pediatrics National Conference and Exhibition today in Washington, D.C.
FDA extends indication for ADHD treatment formulation to adolescent years
October 5th 2005The US Food and Drug Administration (FDA) recently approved Adderall XR (an extended-release formulation of mixed salts of amphetamine) as a once-daily treatment for attention deficit hyperactivity disorder in adolescents 13 to 17 years old. That action bridges an "indication gap" between earlier approval of the product for patients 6 to 12 years old and for older (18 years) adolescents and adults.
Let's get discussion of what causes autism back on track!
September 1st 2005Lately, I've spent a lot of time talking about the alleged link between thimerosal in pediatric vaccines and autism. Most of you have been asked by parents whether immunizations pose a risk of autism as well, and some parents are so frightened by rumors, press reports, and information on the World Wide Web that they forgo immunizations for their children altogether.